Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis
Shots:
- The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries- 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period
- The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions up to @24wks. in patients receiving IMU-838 (45mg & 30mg qd). Rate of treatment-emergent AEs (42.9% vs 43.5%); rate of treatment withdrawals (5.0% vs 7.2%)
- Additionally- the company has reported financial results of Q2’20 with $48.6M in cash and cash equivalents. IMU-838 is an orally available DHOD inhibitor- acts on activated T and B cells and leave other immune cells largely unaffected- allowing the immune system to stay functioning
Ref: Immunic | Image: PRNewswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com